» Articles » PMID: 29576419

Patterns of Care and Outcomes for Glioblastoma in Patients with Poor Performance Status

Overview
Journal J Clin Neurosci
Specialty Neurology
Date 2018 Mar 27
PMID 29576419
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose/objectives: While treatment with tumor resection followed by chemoradiation is generally the accepted standard of care for glioblastoma (GBM), the treatment for patients with poor performance status remains uncertain. Therefore we sought to examine patterns of care and survival outcomes among patients with poor performance status utilizing a large hospital database.

Methods/materials: We queried the National Cancer Database (NCDB) for patients with GBM and Karnofsky performance status (KPS) <60 between 2010 and 2013. Data was collected regarding surgery, radiation therapy and chemotherapy. Logistic regression was used to analyze predictors for utilization of chemoradiation. The Kaplan-Meier method was used to compare survival between those who received chemoradiation to radiation alone and Cox regression was performed to assess covariates associated with survival.

Results: There were 488 patients included in the analysis of which 51.2% received chemoradiation and 46.1% underwent subtotal or gross total resection. None of the factors analyzed were significantly associated with increased likelihood of receiving chemoradiation over radiation alone. Survival data was available for 236 patients that received radiation therapy with and without combination chemotherapy. The median overall survival for those receiving radiation alone was 3.6 months and 8.7 months in those who received chemoradiation (p < 0.001). On multivariable Cox regression, increasing age (HR 1.80-2.10, p = 0.001) was associated with worse survival while subtotal/gross total resection (HR 0.60, p = 0.003) and chemoradiation (HR 0.57, CI 0.40-0.83, p = 0.003) were associated with improved survival.

Conclusion: Even patients with poor performance status had better survival outcomes when they received treatment with chemoradiation over radiation alone.

Citing Articles

Breaking the barrier: Nanoparticle-enhanced radiotherapy as the new vanguard in brain tumor treatment.

Liu S, Li M, Liang B, Sun W, Shao Y, Hu X Front Pharmacol. 2024; 15:1394816.

PMID: 39021831 PMC: 11252536. DOI: 10.3389/fphar.2024.1394816.


Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Senhaji N, Squalli Houssaini A, Lamrabet S, Louati S, Bennis S Int J Mol Sci. 2022; 23(13).

PMID: 35806478 PMC: 9267689. DOI: 10.3390/ijms23137474.


Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale - a bicentric retrospective study.

Barz M, Gerhardt J, Bette S, Aftahy A, Huber T, Combs S BMC Neurol. 2021; 21(1):446.

PMID: 34781889 PMC: 8591917. DOI: 10.1186/s12883-021-02424-0.


Efficacy of sequential radiation and chemotherapy in treating glioblastoma with poor performance status.

Parr E, Sleightholm R, Baine M, Shonka N, Wang T, Zhang C J Neurooncol. 2020; 147(1):91-95.

PMID: 31960233 DOI: 10.1007/s11060-020-03402-1.


EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?.

Armocida D, Pesce A, Frati A, Santoro A, Salvati M J Neurooncol. 2020; 146(2):275-284.

PMID: 31889239 DOI: 10.1007/s11060-019-03364-z.